Funded projects

We carry out a wide range of research projects, often in collaboration with partners in academia and in industry. Explore the diverse portfolio of funded research projects we work on and see how we are delivering global change.



Developing the long-acting pipeline to establish medicines for malaria, tuberculosis and hepatitis C virus with infrastructure for sustainable translational capacity. LONGEVITY is an exciting and ambitious project that aims to develop long-acting injectable medicines to tackle some of the worlds most devastating infectious diseases. Specifically, CELT researchers are working with colleagues across the globe to develop interventions for malaria chemoprophylaxis, tuberculosis prevention and treatment of hepatitis C virus. Co-funding to establish CELT was also provided through this award.

Target exposures of rifapentine/rifabutin for long-acting formulations

Our part in this research is now complete. Supporting a collaboration between CELT and Johns Hopkins University, this work served to better understand the compatibility of tuberculosis treatments with long-acting drug delivery. CELT researchers provided pharmacokinetic modelling support for empirical research being conducted in Baltimore.

An Injectable Implant Providing Long-Acting Drug Delivery for the Treatment of Chronic Disease

An Injectable Implant Providing Long-Acting Drug Delivery for the Treatment of Chronic disease

Our part in this research is now complete. The aim was to develop a new drug delivery system that could be easily injected into the body and would provide long-acting drug release. This technology will address issues caused by poor medication adherence. The drug delivery system is composed of responsive polymer nanoparticles and drug nanoparticles that form a nanocomposite, entrapping a reservoir of drug upon injection into the body. After the drug has been released the materials degrade into non-toxic components and leave the body.

Pharmacological Strategies to use the Levonorgestrel Implant in HIV-infected Women

Our part in this research is now complete. This project underpinned a collaboration between CELT investigators and researchers at the University of Nebraska Medical Centre. Specifically, the work aimed to determine the impact of pharmacogenetics and drug-drug interactions on the pharmacokinetics of contraceptives delivered via subcutaneous implants.

The image includes the text

Harnessing potent next-generation diarylquinolines (DARQs) for long-acting injectable formulations to prevent and treat tuberculosis (TB)

Supporting a collaboration between CELT and Johns Hopkins University to develop long-acting injectable (LAI) formulations of next-generation diarylquinolines (DARQs) with and without possible companion agents for tuberculosis (TB) preventive therapy (TPT) and for use during the continuation phase of active TB treatment. The ultimate goal of this NIH funded project is to develop a ‘one-shot’ DARQ LAI treatment for TPT as well an optimised LAI-based treatment strategy for use in the continuation phase of active TB treatment, each with a sufficient data package to enable an FDA application.

The image includes the text

Repurposing approved drugs as potent antiviral combinations to treat COVID-19 disease

Supporting a collaboration between Queens University Belfast, University of Oxford and CELT investigators, this Medical Research Council (MRC) funded project aims to validate a drug screening pipeline platform for robust and rapid progression of drug combinations against Sars-CoV2 through the pre-clinical pipeline including in vitro analysis, in vivo efficacy studies and pharmacometrics.